JPH1087484A5 - - Google Patents

Info

Publication number
JPH1087484A5
JPH1087484A5 JP1997204344A JP20434497A JPH1087484A5 JP H1087484 A5 JPH1087484 A5 JP H1087484A5 JP 1997204344 A JP1997204344 A JP 1997204344A JP 20434497 A JP20434497 A JP 20434497A JP H1087484 A5 JPH1087484 A5 JP H1087484A5
Authority
JP
Japan
Prior art keywords
formula
compound
use according
cyano
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1997204344A
Other languages
English (en)
Japanese (ja)
Other versions
JPH1087484A (ja
Filing date
Publication date
Priority claimed from DE19640555A external-priority patent/DE19640555A1/de
Application filed filed Critical
Publication of JPH1087484A publication Critical patent/JPH1087484A/ja
Publication of JPH1087484A5 publication Critical patent/JPH1087484A5/ja
Pending legal-status Critical Current

Links

JP9204344A 1996-07-31 1997-07-30 アポプトーシスのモジュレーションのためのイソオキサゾールおよびクロトンアミド誘導体の使用 Pending JPH1087484A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19630838 1996-07-31
DE19640555A DE19640555A1 (de) 1996-10-01 1996-10-01 Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Modulation der Apoptose
DE19640555:6 1996-10-01
DE19630838:0 1996-10-01

Publications (2)

Publication Number Publication Date
JPH1087484A JPH1087484A (ja) 1998-04-07
JPH1087484A5 true JPH1087484A5 (enExample) 2005-05-19

Family

ID=26027963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9204344A Pending JPH1087484A (ja) 1996-07-31 1997-07-30 アポプトーシスのモジュレーションのためのイソオキサゾールおよびクロトンアミド誘導体の使用

Country Status (10)

Country Link
US (1) US6011051A (enExample)
EP (1) EP0821952B1 (enExample)
JP (1) JPH1087484A (enExample)
AT (1) ATE262901T1 (enExample)
AU (1) AU718728B2 (enExample)
CA (1) CA2212207C (enExample)
DE (1) DE59711463D1 (enExample)
DK (1) DK0821952T3 (enExample)
ES (1) ES2218623T3 (enExample)
PT (1) PT821952E (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19711800A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung
DE19860802A1 (de) * 1998-12-30 2000-10-26 Virgene Pharmaceuticals Ag Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren
WO2001021160A2 (en) * 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
US6589992B2 (en) 1999-11-30 2003-07-08 Parker Hughes Institute Inhibiting collagen-induced platelet aggregation
AU4508601A (en) * 1999-11-30 2001-06-18 Parker Hughes Institute Inhibitors of collagen-induced platelet aggregation
US6458930B1 (en) 2000-11-28 2002-10-01 Cytokinetics, Inc. Aspergillus fumigatus cofilin
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
CA2439471A1 (en) 2001-12-28 2003-07-17 Daiichi Suntory Pharma Co., Ltd. Promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors
GB0224014D0 (en) * 2002-10-15 2002-11-27 Oxford Glycosciences Uk Ltd A protein involved in therapy
EA015952B1 (ru) * 2007-05-03 2011-12-30 Пфайзер Лимитед 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
WO2012025217A1 (en) * 2010-08-24 2012-03-01 Algiax Pharmaceuticals Gmbh Novel use of leflunomide and malononitrilamides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
DD297328A5 (de) * 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
AU649421B2 (en) * 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
IL99811A (en) * 1990-10-30 1996-03-31 Roussel Uclaf 3-cycloalkyl-propanamides their tautomer forms and their salts preparation process and compositions containing them
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
EP0538783B1 (de) * 1991-10-23 1995-09-27 Hoechst Aktiengesellschaft N-phenyl-2-cyano-3-hydroxycrotonsäureamidderivate und deren Verwendung als Arzneimittel mit immunmodulatorischer Eigenschaft
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
EP0607777B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 8
DK0607774T3 (da) * 1993-01-08 1999-08-16 Hoechst Ag Anvendelse af leflunomid til inhibering af interleukin 1 alfa
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
ATE174219T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
TW314467B (enExample) * 1993-03-31 1997-09-01 Hoechst Ag
GB9313365D0 (en) * 1993-06-29 1993-08-11 Roussel Lab Ltd Chemical compounds
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin

Similar Documents

Publication Publication Date Title
JPH09505809A (ja) ヒドロキシカルバゾール化合物類による平滑筋移動および増殖の阻害
JP6557684B2 (ja) 線維性疾患の治療に用いられるｐｐａｒ化合物
JP2006515310A5 (enExample)
BRPI0616324A2 (pt) formulaÇço de cÁpsula de pirfenidona e excipientes farmaceuticamente aceitÁveis
JP2002523452A (ja) 肺疾患の治療方法
JP2009280602A (ja) 門脈圧亢進症の予防及び／又は治療
JP2003519228A5 (enExample)
JP2004517843A5 (enExample)
AU2017315357B2 (en) Combination therapies for the treatment of hepatocellular carcinoma
KR20190016478A (ko) Lsd1 억제제를 이용한 다발성 경화증의 치료방법
CN104066324A (zh) 治疗痛风急性发作的方法
CN101068571A (zh) 改善透粘膜给药制剂的吸收的方法
US20020045652A1 (en) Prophylactic or therapeutic drug for renal diseases
TW202615042A (zh) 用於治療進行性纖維化間質性肺病之新穎治療組合
CN1543344A (zh) 治疗尿失禁的芳基(或杂芳基)氮杂茂甲醇衍生物
CN103582481A (zh) A2b腺苷受体拮抗剂用于治疗心肌梗塞后患者的心力衰竭及心律不齐的用途
CN1674903A (zh) 经鼻吸收用组合物
JPH1067662A5 (enExample)
KR101358479B1 (ko) 폐고혈압 치료용 로플루밀라스트
JP2024528731A (ja) 眼癌転移を予防するためのイブジラスト
JPH06506192A (ja) 阻害剤
TW202247844A (zh) 吡咯并嘧啶類化合物的用途
AU2013362755A1 (en) Uses and methods for the treatment of liver diseases or conditions
JP2007504223A5 (enExample)
JP2003501462A (ja) 受容体アゴニストおよびアンタゴニスト